Polatuzumab vedotin (Polivy)

From HemOnc.org - A Hematology Oncology Wiki
Jump to navigation Jump to search

General information

Class/mechanism from the NCI Drug Dictionary: An antibody-drug conjugate (ADC) composed of a monoclonal antibody directed against B-cell antigen receptor complex-associated protein beta chain (CD79B) conjugated, via a protease-cleavable peptide linker, to monomethyl auristatin E (MMAE), an auristatin derivative and a potent microtubule inhibitor, with potential antineoplastic activity. Upon administration, polatuzumab vedotin selectively binds to CD79B, a protein which is abundantly expressed on the surface of B-cells. Upon internalization and proteolytic cleavage, MMAE binds to tubulin and inhibits its polymerization, resulting in G2/M phase arrest and tumor cell apoptosis.
Route: IV
Extravasation: neutral

Diseases for which it is used

Patient drug information

History of changes in FDA indication

History of changes in EMA indication

  • 2020-01-16: Initial conditional approval

History of changes in Health Canada indication

  • 2020-07-09: Initial notice of compliance with conditions
  • 2023-01-20: Conditions were met

History of changes in PMDA indication

Also known as

  • Code name: DCDS4501A, FCU-2711, RG-7596
  • Generic name: polatuzumab vedotin-piiq
  • Brand name: Polivy